Transcode Therapeutics, INC 10-Q quarterly reports

TransCode Therapeutics reports increased operating losses and a continued need for capital, with cash reserves projected to last only until year-end 2026.

TransCode Therapeutics reports a net loss of $17.8 million for Q1 2026 while securing new capital through a $14 million standby equity purchase agreement.

TransCode Therapeutics reports a significant Q3 with a strategic acquisition, a $25 million investment, and advancement in its lead clinical programs, despite increased net losses.

TransCode Therapeutics reported increased net loss for the first half of 2025 despite reduced operating expenses, while its lead cancer therapeutic candidate, TTX-MC138, showed positive safety data in its Phase I/II clinical trial.

TransCode Therapeutics reports a net loss of $12.1 million for Q1 2025 and faces potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement.

TransCode Therapeutics' Q3 2024 report reveals ongoing losses, a cash runway into late 2024, and challenges with Nasdaq listing compliance.

TransCode Therapeutics reported its second quarter 2024 financial results, highlighted by ongoing clinical trial progress but also facing potential delisting from the Nasdaq Capital Market.

TransCode Therapeutics reported a net loss of $3.3 million for the first quarter of 2024 and is facing potential delisting from the Nasdaq Capital Market.